Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease
Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease
复制标题
DOI：
10.1034/j.1600-0560.2002.290605.x
复制
发表时间：
2002-07-01
影响因子：
1.7
通讯作者：
Kaufmann, R
中科院分区：
文献类型：
--
作者：
Kneisel, L;Strebhardt, K;Kaufmann, R
背景：通过 Breslow 法测量的原发性恶性黑色素瘤的最大厚度是目前最重要的预后因素。然而，根据 Breslow 的说法，一些薄黑色素瘤（小于或等于 0.75 毫米）应该具有良好的预后，但由于其转移能力而可能致命。 方法：在我们的研究中，使用针对 PLK1 和 基-67。将 22 例在随访 5 年内发生转移的黑色素瘤的免疫反应性与一组 14 例未转移的黑色素瘤进行比较。两名独立研究人员评估了染色切片。使用 Mann-Whitney U 检验对有转移和无转移的黑色素瘤之间 PLK1 和 Ki-67 指数的差异进行统计检验。结果：与无转移的黑色素瘤相比，有转移的恶性黑色素瘤的 PLK1 表达水平显着升高（中位数为 60.00% vs. 37.98%；p = 0.000053）。两组之间 Ki-67 指数的差异并不显着（中位数为 6.35% vs. 4.53%；p = 0.150473）。 结论：我们的结果表明，薄黑色素瘤中 PLK1 的表达是识别转移高风险患者的可靠标志物。
Background: The maximum thickness of a primary malignant melanoma as measured by Breslow's method is currently the most important prognostic factor. However, some thin melanomas (less than or equal to 0.75 mm), which should have an excellent prognosis according to Breslow, can be lethal due to their ability to metastasize.Methods: In our study, thin malignant melanomas (less than or equal to 0.75 mm) from 36 patients were analyzed with immunohistochemical techniques using monoclonal antibodies directed against PLK1 and Ki-67. The immunoreactivity of 22 melanomas which developed metastases within 5 years of follow-up was compared with a group of 14 non-metastasized melanomas. Two independent investigators evaluated stained sections. Differences of PLK1 and Ki-67 indices between melanomas with and without metastases were tested statistically using the Mann-Whitney U -test.Results: Malignant melanomas with metastases expressed PLK1 at markedly elevated levels compared to melanomas without metastases (median, 60.00% vs. 37.98%; p = 0.000053). The difference of the Ki-67 index between both groups was not significant (median, 6.35% vs. 4.53%; p = 0.150473).Conclusions: Our results suggest that PLK1 expression in thin melanomas is a reliable marker to identify patients at high risk for metastases.